BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19494397)

  • 1. Hepatitis B infection in haematopoietic stem cell transplantation: still unresolved.
    Hsiao LT; Chiou TJ; Gau JP; Liu JH; Tzeng CH; Chen PM
    Hong Kong Med J; 2009 Jun; 15(3 Suppl 3):42-4. PubMed ID: 19494397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab.
    Moses SE; Lim ZY; Sudhanva M; Devereux S; Ho AY; Pagliuca A; Zuckerman M; Mufti GJ
    J Med Virol; 2006 Dec; 78(12):1560-3. PubMed ID: 17063522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B virus among hematopoietic stem cell transplant recipients: Antiviral impact in seroconversion, engraftment, and mortality in a Latin American center.
    Buzo BF; Ramos JF; Marques Rossetti RA; Salles N; Mendrone-Júnior A; Rocha V; de Seixas Santos Nastri AC
    Transpl Infect Dis; 2020 Apr; 22(2):e13243. PubMed ID: 31901206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal.
    Cerva C; Maffongelli G; Svicher V; Salpini R; Colagrossi L; Battisti A; Mariotti B; Cerretti R; Cudillo L; Sarmati L
    BMC Infect Dis; 2017 Aug; 17(1):566. PubMed ID: 28806922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor.
    Cerva C; Colagrossi L; Maffongelli G; Salpini R; Di Carlo D; Malagnino V; Battisti A; Ricciardi A; Pollicita M; Bianchi A; Picardi A; Cudillo L; Cerretti R; De Angelis G; Cantonetti M; Andreoni M; Perno CF; Arcese W; Svicher V; Sarmati L
    Clin Microbiol Infect; 2016 Nov; 22(11):946.e1-946.e8. PubMed ID: 27475741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of prophylactic Anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors.
    Hui CK; Lie A; Au WY; Ma SY; Leung YH; Zhang HY; Sun J; Cheung WW; Chim CS; Kwong YL; Liang R; Lau GK
    Am J Transplant; 2005 Jun; 5(6):1437-45. PubMed ID: 15888052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation.
    Uhm JE; Kim K; Lim TK; Park BB; Park S; Hong YS; Lee SC; Hwang IG; Koh KC; Lee MH; Ahn JS; Kim WS; Jung CW; Kang WK
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):463-8. PubMed ID: 17382252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country.
    Murt A; Elverdi T; Eskazan AE; Salihoglu A; Ar MC; Ongoren S; Baslar Z; Soysal T
    Ann Hematol; 2020 Nov; 99(11):2671-2677. PubMed ID: 32737632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantation: a multi-institutional experience from an HBV endemic area.
    Wu Y; Chen Y; Zhu P; Ye B; Lu Y; Shi J; Tan Y; Zhao Y; Yu J; Lai X; Lan J; Si T; Ni L; Huang H; Luo Y
    Ann Hematol; 2022 Mar; 101(3):631-641. PubMed ID: 34981143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study.
    Seto WK; Chan TS; Hwang YY; Wong DK; Fung J; Liu KS; Gill H; Lam YF; Lau EHY; Cheung KS; Lie AKW; Lai CL; Kwong YL; Yuen MF
    Hepatology; 2017 May; 65(5):1451-1461. PubMed ID: 28027590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome.
    Mikulska M; Nicolini L; Signori A; Rivoli G; Del Bono V; Raiola AM; Di Grazia C; Dominietto A; Varaldo R; Ghiso A; Bacigalupo A; Viscoli C
    Clin Microbiol Infect; 2014 Oct; 20(10):O694-701. PubMed ID: 24575948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor.
    Knöll A; Boehm S; Hahn J; Holler E; Jilg W
    J Viral Hepat; 2007 Jul; 14(7):478-83. PubMed ID: 17576389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation.
    Wu Y; Huang H; Luo Y
    Front Immunol; 2020; 11():610500. PubMed ID: 33613534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.
    Lau GK; He ML; Fong DY; Bartholomeusz A; Au WY; Lie AK; Locarnini S; Liang R
    Hepatology; 2002 Sep; 36(3):702-9. PubMed ID: 12198664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation.
    Yoo JJ; Cho EJ; Cho YY; Lee M; Lee DH; Cho Y; Lee JH; Yu SJ; Yoon SS; Yoon JH; Kim YJ
    Liver Int; 2015 Dec; 35(12):2530-6. PubMed ID: 26053357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High risk of hepatitis B-virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody-positive patients.
    Matsue K; Aoki T; Odawara J; Fujiwara H; Iwama K; Kimura S; Yamakura M; Takeuch M
    Eur J Haematol; 2009 Oct; 83(4):357-64. PubMed ID: 19508685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
    Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
    Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The influence of hepatitis B virus infection on patients undergoing allogeneic hematopoietic stem cell transplantation].
    Liang C; Jiang EL; Huang Y; Yan ZS; Yang DL; He Y; Ma QL; Wei JL; Wang M; Feng SZ; Qiu LG; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2010 Jul; 31(7):456-60. PubMed ID: 21122399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients.
    Hsiao LT; Chiou TJ; Liu JH; Chu CJ; Lin YC; Chao TC; Wang WS; Yen CC; Yang MH; Tzeng CH; Chen PM
    Biol Blood Marrow Transplant; 2006 Jan; 12(1):84-94. PubMed ID: 16399572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.